EcoDrugPlus

Solute Carrier Family 18 Member 2

Ensembl ID : ENSOJAG00000011223
Gene Symbol: SLC18A2
1 Cross references
216 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSOJAG00000000290
Gene Symbol: SLC29A1
1 Cross references
210 Possible Orthologues:

Solute Carrier Family 29 Member 1a

Ensembl ID : ENSOJAG00000016059
Gene Symbol: SLC29A1A
1 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 1

Ensembl ID : ENSOJAG00000004399
Gene Symbol: SLC5A1
1 Cross references
247 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSOJAG00000023827
Gene Symbol: SLC5A2
1 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1a

Ensembl ID : ENSOJAG00000012121
Gene Symbol: SLC6A1A
1 Cross references
205 Possible Orthologues:

Solute Carrier Family 6 Member 1b

Ensembl ID : ENSOJAG00000015157
Gene Symbol: SLC6A1B
1 Cross references
209 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSOJAG00000001228
Gene Symbol: SLC6A2
1 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSOJAG00000018621
Gene Symbol: SLC6A3
1 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4a

Ensembl ID : ENSOJAG00000007701
Gene Symbol: SLC6A4A
1 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSOJAG00000011958
Gene Symbol: SLC6A9
1 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3, Tandem Duplicate 2

Ensembl ID : ENSOJAG00000003301
Gene Symbol: SLC9A3.2
1 Cross references
234 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).